www.hep-druginteractions.org

Lenvatinib PK Fact Sheet

LIVERPOO

Page 1 of 2

Prepared July 2022

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

Generic Name	Lenvatinib
Trade Name	Kisplyx [®] , Lenvima [®] .
Class	HCC receptor tyrosine kinase inhibitor.
Molecular Weight	522.96
Structure	H ₂ N CH ₃ —SO ₃ H CH ₃ —SO ₃ H

Summary of Key Pharmacokinetic Parameters

Linearity/non-linearity	Exposure to lenvatinib increased in direct proportion to the administered dose over the range of 3.2 - 32 mg once-daily.
Steady state	No data
Elimination half-life	~28 h
C _{max}	291 ng/mL (12 mg QD, at steady state in patients with solid tumors ¹).
C24	22.3 ng/mL, (12 mg QD, at steady state in patients with solid tumors ¹).
AUC	2059 ng*h/mL, (12 mg QD, at steady state in patients with solid tumors ¹).
Ттах	1-4 h
Bioavailability	~85%
Absorption	Administration with food delays T_{max} by 2 h.
Protein Binding	98-99%
Volume of Distribution	50.5-92 L
CSF:Plasma ratio	No data
Renal Clearance	25%
Renal Impairment	AUC increased by 101%, 90%, and 122% in patients with mild, moderate, and severe renal impairment, respectively. Refer to product label for dosage adjustment.
Hepatic Impairment	AUC increased by 119%, 107%, and 180% in patients with mild, moderate, and severe hepatic impairment, respectively. Refer to product label for dosage adjustment.
Metabolism and Distribution	
Metabolised by	СҮРЗА4
Inducer of	None expected.
Inhibitor of	None expected.
Transported by	P-gp, BCRP.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX. We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

www.hep-druginteractions.org

Lenvatinib PK Fact Sheet

Prepared July 2022

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

References

Unless otherwise stated (see below), information is from: Kisplyx Summary of Product Characteristics, Eisai Ltd. Lenvima Prescribing Information, Eisai Inc.

1. Ikeda, M., Okusaka, T., Mitsunaga, S., et al. 2016. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research 22(6):1385–1394.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

Page 2 of 2